Summary.-Aprotinin was bound and endocytosed by Landschutz ascites carcinoma (LAC) cells in vitro. Addition of the antiprotease to cultures of these cells led to a dosedependent growth-inhibitory and cytotoxic effect. In mice inoculated with LAC cells and treated with aprotinin there was a transient reduction in both the number and concentration of recovered ascites cells during the early phase of tumour growth. This was accompanied by a temporary increase in the proportion of peritoneal phagocytes (mononuclear phagocytes and polymorphonuclear leucocytes) relative to carcinoma cells. However, the number and concentration of ascites cells eventually achieved was comparable in saline and aprotinin-treated animals.
THE low-molecular-weight polypeptide aprotinin (Trasylol) which is isolated from bovine lung, binds specifically to sialyl residues, and has been used to demonstrate their presence on the surfaces of a variety of animal cells (Kiernan and Stoddart, 1973) including human lymphocytes (Stoddart et al., 1974) . In addition to its carbohydrate-binding properties, aprotinin is a broad-spectrum antiprotease which inhibits the enzymes trypsin, chymotrypsin and plasma kallikrein (Werle, 1970) .
Of the wide range of naturally-occurring and synthetic protease inhibitors currently available, some, including aprotinin, impair the growth of malignant cells and their non-malignant homologues in vitro (Coetz et al., 1972; Latner et al., 1973; Roblin et al., 1975) . Thus, although the original claim of Schnebli and Burger (1972) that the growth-inhibitory effects of protease inhibitors are directed selectively against malignant tumour cells, has not beeni suibstantiated (Hynes, 1 976; Schuiebli, 1975) nevertheless, inhibition of maligniant cell growth by protease inhibitors lends to the view (Bosmann and Hall;  Easty and Easty, 1976;  Hynes, 1976; Schnebli, 1975; Sylven, 1967 ) that tumour cell proteases potentiate the growth of malignant tumours. However, evaluation of aprotinin as an anti-tumour agent in vivo by various authors has produced variable results (Back et al., 1966; Back and Steger, 1976; Cliffton and Agostino, 1964; Giraldi et al., 1977; Latner et al., 1974; Thomson et al., 1977) .
In this study, we have used an indirect immunoperoxidase technique to examine the binding of aprotinin by Landschuitz ascites carcinoma (LAC) cells. Also, in view of reports that a natural protease inhibitor (soybean trypsin inhibitor) impairs growth of ascites tumours (Whur et al., 1973; Verloes et al., 1978) (Watson, 1958) and lead citrate (Reynolds, 1963) prior to examination in an AEI EM6B transmission electron microscope.
In vitro growth and viability studies.-Two dilutions of aprotinin (5 and 125 KIU) were added to cultures of ascites cells (2 x 105 cells in 0-2 ml) in MEM supplemented with 10% heat-inactivated foetal bovine serum within flat-bottomed microcultures plates (3040 Falcon Plastics). Each treatment was replicated 6 times. At 24 and 48 h the culture supernatants were replaced by fresh medium containing equivalent doses of aprotinin to those added at the start of the culture. Cell numbers were estimated by haemocytometry and viability assessed by trypan-blue exclusion at 24, 48 and 72 h.
In vivo experiments.-Growth of the tumour was measured in animals injected with 106 viable ascites cells. Each group received either 0 5 ml aprotinin (5,000 KIU) or an equivalent volume of Dulbecco "A" phosphate buffered saline (PBS) i.p. at the same time as tumour injection and twice daily thereafter. At various times after cell challenge 12 mice, 6 from each treatment group, were killed and growth measurements conducted.
Monitoring of tumour growth.-Mice were killed by terminal ether anaesthesia. At early stages of tumour development (Days 2 and 4) when there was little measurable ascitic fluid, free ascites cells were removed by lavaging the peritoneal cavity with 10 ml PBS containing heparin (2 IU/ml). At later stages, a midline incision was made in the abdominal wall, the ascitic fluid withdrawn and placed in a pre-weighed test tube. The remaining fluid was removed by swabbing the peritoneal cavity with pre-weighed cotton wool. Since the sp. gr. of ascitic fluid approximates closely to 1 (Wheatley and Ambrose, 1964 ) the weight of fluid (measured correct to 10-3 g) corresponded to the volume (ml) of fluid present. Confirmation of ascitic-fluid volume was achieved by weighing the mice (correct to 10-2 g) before and after removal of the tumour. Total free ascites cells was then given by the product of ascitic fluid volume and the cell count per ml, which, together with cell viability was estimated by haemocytometry.
Characterization of peritoneal cells.-Peritoneal cavities of mice injected i.p. with tumour cells, and either aprotinin or saline,
were lavaged with heparin-containing medium and the aspirates centrifuged to obtain cell pellets which were fixed in glutaraldehyde followed by osmium tetroxide and then embedded in TAAB epoxy resin. Cytodiagnostic observations on the cells within the pellets together with counts of the different cell types present, were made on 1 ,um sections stained with toluidine blue. 
RESULTS
Binding of aprotinin Using the indirect immunoperoxidase staining procedure to localise cell-bound aprotinin, an electron-dense precipitate was observed at the surfaces of LAC cells which had been fixed in glutaraldehyde prior to incubation in the protease inhibitor (Fig. 1) . The electron-dense precipitate which was some 30-50 nm wide, was adherent to the outer osmiophilic "leaflet" (zone?) of the plasma membrane, revealing that aprotinin had bound to moieties in the glycocalyx region of the tumour-cell surface (Inset, Fig. 1 ). There was no surface staining visible on those cells which had not been incubated in aprotinin prior to the indirect immunoperoxidase staining.
Ultrastructural studies on LAC cells which had been incubated in medium containing aprotinin prior to fixation and indirect immunoperoxidase staining (Fig. 2 Effect8 of aprotinin on tumour growth G-rowth of the tumour, measured by the number of recoverable ascites cells within both saline and aprotinin-treated animals at various times after injection of 106 viable tumour cells is shown in Fig. 4 (Back and Leblanc, 1977; Kinjo et al., 1963; Verloes et al., 1978; Whur et al., 1973) (Hynes, 1976; Talmadge et al., 1974) . In vtio however, such effects are t-likely to be less pronounced, due to more rapid catabolism of aprotinin and its widespread binding to ubiquitous sialyl moieties; factors which probably account for its relative inefficiency as a therapeutic agent in the tumour-bearing host, and which are likely to be exaggerated by rapid cell replication and copious ascitic fluid production.
The transient anti-tumour effect observed in vivo, as evidenced by reduced cell numbers and an increased proportion of host phagocytic cells, could reflect a cytotoxic effect of the drug accompanied by stimulation of the temporary reticuloendothelial response to the tumour (El Hassan and Stuart, 1965) . Indeed, Latner and Turner (1976) have claimed that aprotinin does influence the host's immune response during tumour growth. Using comparable treatment regimes to that used in the present study, Latner et al. (1974) and Back and Steger (1976) were able to demonstrate a clear inhibitory effect of aprotinin against growth of solid murine tumours. It is our opinion that ascitic tumours such as LAC may provide a less favourable milieu for full expression of the anti-tumour potential of this naturallyoccurring antiprotease.
